Undisclosed pan-EGFR degrader / AstraZeneca, Pinetree Therap - LARVOL DELTA

Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca (PRNewswire) - "Pinetree Therapeutics, Inc...today announced it has entered into an exclusive option and global license agreement with AstraZeneca...for a preclinical EGFR degrader candidate....Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license Pinetree's preclinical EGFR degrader for global development and commercialization. In exchange, Pinetree will receive upfront and near-term payments of up to $45 million and is eligible to receive additional development and commercial milestone payments for a total deal value of over $500 million, as well as tiered royalties on net sales worldwide."

Licensing / partnership • Oncology